EP3317246A4 - SPECIFIC CONJUGATION OF A CELL BINDING MOLECULE - Google Patents
SPECIFIC CONJUGATION OF A CELL BINDING MOLECULE Download PDFInfo
- Publication number
- EP3317246A4 EP3317246A4 EP15772625.8A EP15772625A EP3317246A4 EP 3317246 A4 EP3317246 A4 EP 3317246A4 EP 15772625 A EP15772625 A EP 15772625A EP 3317246 A4 EP3317246 A4 EP 3317246A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- cell
- binding molecule
- specific conjugation
- conjugation
- specific
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/20—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a carbon atom of an acyclic unsaturated carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/76—Unsaturated compounds containing keto groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrrole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IB2015/055051 WO2015151080A2 (en) | 2015-07-04 | 2015-07-04 | Specific conjugation of a cell-binding molecule |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3317246A2 EP3317246A2 (en) | 2018-05-09 |
EP3317246A4 true EP3317246A4 (en) | 2019-02-27 |
Family
ID=54241397
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP15772625.8A Pending EP3317246A4 (en) | 2015-07-04 | 2015-07-04 | SPECIFIC CONJUGATION OF A CELL BINDING MOLECULE |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP3317246A4 (zh) |
JP (1) | JP6700321B2 (zh) |
CN (2) | CN108811499B (zh) |
CA (1) | CA2991384C (zh) |
WO (1) | WO2015151080A2 (zh) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015109391A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
ES2785551T3 (es) | 2014-06-30 | 2020-10-07 | Glykos Finland Oy | Derivado de sacárido de una carga útil tóxica y sus conjugados con anticuerpos |
WO2015155753A2 (en) * | 2015-08-10 | 2015-10-15 | Suzhou M-Conj Biotech Co., Ltd | Novel linkers and their uses in specific conjugation of drugs to a biological molecule |
JP7330515B2 (ja) * | 2015-08-10 | 2023-08-22 | ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ. | 新規な連結体及び生体分子と薬物との特異的共役におけるその使用 |
AU2016202632B2 (en) * | 2016-02-04 | 2021-09-09 | Hangzhou Dac Biotech Co, Ltd | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof |
TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
WO2018009916A1 (en) | 2016-07-07 | 2018-01-11 | The Board Of Trustees Of The Leland Stanford Junior University | Antibody adjuvant conjugates |
CN106474147B (zh) * | 2016-10-14 | 2022-07-05 | 上海颉隆投资管理有限公司 | 一种预防和控制人乳头状瘤病毒感染的敷料及其制备方法 |
KR20220147720A (ko) * | 2016-11-14 | 2022-11-03 | 항저우 디에이씨 바이오테크 씨오, 엘티디 | 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용 |
NZ755835A (en) | 2017-01-17 | 2023-12-22 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
CN109444349B (zh) * | 2018-12-26 | 2020-07-07 | 中国科学院地球化学研究所 | 一种测定室内植物代谢水利用份额和实际需水量的方法 |
WO2020190725A1 (en) | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
CN111773183B (zh) * | 2019-04-04 | 2022-02-01 | 沈阳药科大学 | 一种Cu(DDC)2纳米核脂质体及其制备方法和应用 |
SG11202111402PA (en) | 2019-05-14 | 2021-11-29 | Nuvation Bio Inc | Anti-cancer nuclear hormone receptor-targeting compounds |
KR20220029725A (ko) | 2019-06-29 | 2022-03-08 | 항저우 디에이씨 바이오테크 씨오, 엘티디 | 세포-결합 분자-튜불리신 유도체 접합체 및 이의 제조 방법 |
CN110308145A (zh) * | 2019-07-10 | 2019-10-08 | 迪瑞医疗科技股份有限公司 | 一种沙眼衣原体糖原检测试剂、沙眼衣原体糖原检测试纸条及其制备方法 |
CN112341521A (zh) * | 2019-08-09 | 2021-02-09 | 上海翰森生物医药科技有限公司 | 一种小分子活性化合物及其抗体偶联物、其制备方法和医药用途 |
US11952349B2 (en) | 2019-11-13 | 2024-04-09 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
CN110835405B (zh) * | 2019-11-28 | 2020-09-15 | 安阳师范学院 | 用于肿瘤检测的高分子生物传感器及制备方法及应用 |
CN111879684B (zh) * | 2020-06-18 | 2021-12-21 | 山东大学 | 一种基于流式细胞术的吞噬细胞功能检测方法 |
CN113925973A (zh) * | 2020-07-14 | 2022-01-14 | 辽宁中健医药科技有限公司 | 一种多肽偶联药物及其制备方法和应用 |
CN112409242B (zh) * | 2020-09-25 | 2022-07-12 | 华南农业大学 | 一种氨氯地平半抗原、人工抗原、抗体及其制备方法和应用 |
CN112379029B (zh) * | 2020-11-10 | 2022-03-08 | 苏州艾迪迈医疗科技有限公司 | 一种检测血液中抗新型冠状病毒药物浓度的方法 |
US20240148888A1 (en) * | 2021-02-23 | 2024-05-09 | Children's Medical Center Corporation | Intercellular adhesion molecule 1 (icam1) antibody drug conjugate and uses thereof |
BR112023019420A2 (pt) | 2021-03-23 | 2023-10-24 | Nuvation Bio Inc | Compostos de direcionamento ao receptor de hormônio nuclear anticâncer |
CN113214403B (zh) * | 2021-04-25 | 2023-06-09 | 重庆威斯腾前沿生物研究院有限责任公司 | 一种链霉亲和素磁珠及其制备方法 |
CN113913535A (zh) * | 2021-11-30 | 2022-01-11 | 江西农业大学 | 一种用于鉴别蓝孔雀白羽性状的因果基因及其应用 |
WO2023125349A1 (zh) * | 2021-12-27 | 2023-07-06 | 山东先声生物制药有限公司 | 抗gucy2c抗体及其应用 |
CN116239513B (zh) * | 2023-05-05 | 2023-08-18 | 天津凯莱英制药有限公司 | Mmae关键中间体的制备方法、mmae的制备方法和抗体偶联药物 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101723961A (zh) * | 2009-12-08 | 2010-06-09 | 刘超美 | 一种β-内酰胺类双抗生素化合物及其制备方法和用途 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0228358D0 (en) * | 2002-12-05 | 2003-01-08 | Unilever Plc | Improvements relating to fabric treatment |
EP2276506A4 (en) * | 2008-04-30 | 2014-05-07 | Immunogen Inc | EFFICIENT CONJUGATES AND HYDROPHILIC BINDER |
EP2610263A1 (de) * | 2011-12-30 | 2013-07-03 | Brossmer, Reinhard | Sialinsäure-Dimere |
JP6133431B2 (ja) * | 2012-11-24 | 2017-05-24 | ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ.Hangzhou Dac Biotech Co.,Ltd. | 親水性連結体及び薬物分子と細胞結合分子との共役反応における親水性連結体の使用 |
CN103933575B (zh) * | 2013-01-23 | 2017-09-29 | 上海新理念生物医药科技有限公司 | 一种三齿型连接子及其应用 |
US11229711B2 (en) * | 2013-06-06 | 2022-01-25 | Magenta Therapeutics, Inc. | Linkers for antibody-drug conjugates and related compounds, compositions, and methods of use |
CN103467590B (zh) * | 2013-09-02 | 2016-04-13 | 深圳大学 | 生物偶联体、制备其的嘌呤类化合物、合成方法、药用制剂以及其在免疫调节中的应用 |
CN115124573A (zh) * | 2013-09-02 | 2022-09-30 | 杭州多禧生物科技有限公司 | 应用于细胞结合分子-药物共轭体的新型细胞毒性分子 |
-
2015
- 2015-07-04 CN CN201580082141.5A patent/CN108811499B/zh active Active
- 2015-07-04 JP JP2017568455A patent/JP6700321B2/ja active Active
- 2015-07-04 CA CA2991384A patent/CA2991384C/en active Active
- 2015-07-04 WO PCT/IB2015/055051 patent/WO2015151080A2/en active Application Filing
- 2015-07-04 CN CN202110978276.7A patent/CN113698335A/zh active Pending
- 2015-07-04 EP EP15772625.8A patent/EP3317246A4/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101723961A (zh) * | 2009-12-08 | 2010-06-09 | 刘超美 | 一种β-内酰胺类双抗生素化合物及其制备方法和用途 |
Non-Patent Citations (8)
Title |
---|
A. S. HASHMI: "Photochemical Synthesis of Prochiral Dialkyl 3,3-Dialkylcyclopropene-1,2- dicarboxylates with Facial Shielding Substituents and Related Substrates", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 26 November 2001 (2001-11-26), GB, pages 4705 - 4732, XP055450906, ISBN: 978-0-08-097742-3 * |
DIRK HEYL ET AL: "Facile Direct Synthesis of Acetylenedicarboxamides", SYNTHESIS, vol. 46, no. 11, 17 March 2014 (2014-03-17), STUTTGART, DE., pages 1463 - 1468, XP055450898, ISSN: 0039-7881, DOI: 10.1055/s-0033-1341101 * |
GRETE VAN WUYTSWINKEL ET AL: "A convergent synthesis of heterocyclic dendrimers using the 1,3-dipolar cycloaddition reaction of organic azides and acetylenedicarboxylate esters", ROYAL CHEMICAL SOCIETY. JOURNAL. PERKIN TRANSACTIONS 1, vol. 1, no. 9, 1 January 2000 (2000-01-01), GB, pages 1337 - 1340, XP055450907, ISSN: 1470-4358, DOI: 10.1039/b000025f * |
J. L. CHARLTON: "'Synthesis of chiral Esters of Acetylenedicarboxylic Acid'", TETRAHEDRON LETTERS, vol. 35, no. 34, 22 August 1994 (1994-08-22), pages 6243 - 6246, XP055450908 * |
JOÃO P. M. NUNES ET AL: "Functional native disulfide bridging enables delivery of a potent, stable and targeted antibody-drug conjugate (ADC)", CHEMICAL COMMUNICATIONS, vol. 51, no. 53, 1 January 2015 (2015-01-01), pages 10624 - 10627, XP055539726, ISSN: 1359-7345, DOI: 10.1039/C5CC03557K * |
JOHN A. MIKROYANNIDIS ET AL: "Synthesis, photophysics, structure-tunable photoluminescence, and electrochemical properties of soluble poly(p-phenylenevinylene)-based polymers with adjacent 1,3,4-oxadiazoles in the backbone", JOURNAL OF POLYMER SCIENCE, PART A: POLYMER CHEMISTRY, vol. 43, no. 14, 1 January 2005 (2005-01-01), US, pages 3079 - 3090, XP055450904, ISSN: 0887-624X, DOI: 10.1002/pola.20771 * |
LOURDES CASTAÑEDA ET AL: "Acid-cleavable thiomaleamic acid linker for homogeneous antibody-drug conjugation", CHEMICAL COMMUNICATIONS, vol. 49, no. 74, 1 January 2013 (2013-01-01), pages 8187 - 8189, XP055539224, ISSN: 1359-7345, DOI: 10.1039/c3cc45220d * |
RAVI V. J. CHARI ET AL: "Antibody-Drug Conjugates: An Emerging Concept in Cancer Therapy", ANGEWANDTE CHEMIE INTERNATIONAL EDITION, vol. 53, no. 15, 7 April 2014 (2014-04-07), pages 3796 - 3827, XP055167825, ISSN: 1433-7851, DOI: 10.1002/anie.201307628 * |
Also Published As
Publication number | Publication date |
---|---|
CN108811499A (zh) | 2018-11-13 |
CN108811499B (zh) | 2021-09-24 |
CA2991384A1 (en) | 2015-10-08 |
CN113698335A (zh) | 2021-11-26 |
WO2015151080A2 (en) | 2015-10-08 |
EP3317246A2 (en) | 2018-05-09 |
CA2991384C (en) | 2022-11-08 |
JP6700321B2 (ja) | 2020-05-27 |
JP2018523639A (ja) | 2018-08-23 |
WO2015151080A3 (en) | 2016-06-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3317246A4 (en) | SPECIFIC CONJUGATION OF A CELL BINDING MOLECULE | |
EP3313857A4 (en) | POLYMER-CYCLODEXTRIN LIPID CONJUGATES | |
EP3297649A4 (en) | Peptide oligonucleotide conjugates | |
EP3206710A4 (en) | Incretin-insulin conjugates | |
EP3319936A4 (en) | PLACES OF CONDUCT FOR THE CONJUGATION OF CELL BINDING MOLECULES | |
EP3119885A4 (en) | Antibody-fynomer conjugates | |
EP3137114B8 (en) | Anti-ptk7 antibody-drug conjugates | |
EP3135358A4 (en) | Top toy | |
EP3368033A4 (en) | THERAPEUTIC HONEY CANNABINOID COMPOSITION | |
EP3448417A4 (en) | SOUND CONJUGATES OF INSULIN-INCRETIN | |
EP3302439A4 (en) | Therapeutic composition | |
EP3388125A4 (en) | SHOOTING TOY | |
EP3525808A4 (en) | ANTIBODY-POLYMER-DRUG CONJUGATES | |
EP3334500A4 (en) | MULTILIGAND-ACTIVE CONJUGATES AND USES THEREOF | |
EP3220961A4 (en) | Therapeutic vitamin d conjugates | |
EP3703681A4 (en) | IMIPRIDONES FOR GLIOMAS | |
EP3261678B8 (en) | Antibody-urease conjugates for therapeutic purposes | |
EP3152223A4 (en) | Peptide-drug conjugates | |
EP3496755A4 (en) | CONJUGATES OF TGF- ANTAGONISTS. | |
EP3316885A4 (en) | IMMUNOCONJUGATED ANTIBODIES SN-38 WITH A CL2A | |
EP3430033A4 (en) | CONJUGATES OF INSULIN-INCRETIN | |
EP3001833A4 (en) | Purification of nanoparticle-antibody conjugates | |
EP3127915A4 (en) | Targeting molecule and utilization thereof | |
EP3347042A4 (en) | MULTIVALENT CONJUGATES WITH VIRUSUAL PARTICLES | |
EP3389719A4 (en) | PEPTIDE OLIGONUCLEOTIDE CONJUGATES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20180201 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: C07C0059760000 Ipc: A61K0047680000 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20190124 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 31/00 20060101ALI20190118BHEP Ipc: C07K 16/28 20060101ALI20190118BHEP Ipc: A61P 35/00 20060101ALI20190118BHEP Ipc: C07C 237/52 20060101ALI20190118BHEP Ipc: C07D 207/46 20060101ALI20190118BHEP Ipc: A61P 37/00 20060101ALI20190118BHEP Ipc: C07C 59/76 20060101ALI20190118BHEP Ipc: C07D 417/14 20060101ALI20190118BHEP Ipc: A61K 47/68 20170101AFI20190118BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20200914 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230516 |